title: Factors associated with frovatriptan response in patients with migraine: A prospective, observational study.
abstract: BACKGROUND
  Almost one-third of patients with migraine do not adequately respond to triptans. We examined factors contributing to frovatriptan response in patients with migraine.
  
  
  METHODS
  We enrolled new patients with migraine who consecutively visited our headache clinic. Eligible patients were instructed to take 2.5 mg of frovatriptan as soon as possible after migraine attack. The responsiveness was determined by whether headache was relieved or absent within 4 hours after the intake of frovatriptan. We assessed frovatriptan to be efficacious when headache responded to its administration in at least one of two successive migraine attacks and inefficacious when headache was not relieved in either attack. We included demographic, clinical and psychiatric variables in the analysis of factors associated with frovatriptan response.
  
  
  RESULTS
  Of 128 eligible patients, 28 (21.9%) experienced frovatriptan inefficacy. In 24 patients with current major depressive disorder, 12 (50.0%) had frovatriptan inefficacy. Only current major depressive disorder was identified as a risk factor for inefficacy (odds ratio = 5.500, 95% confidence interval 2.103-14.382, ITALIC! p = 0.001).
  
  
  CONCLUSIONS
  Depression may be a risk factor of frovatriptan inefficacy in patients with migraine, even though half of patients with major depressive disorder respond to frovatriptan.
authors.affiliation: Department of Neurology, School of Medicine, Kyungpook National University, Republic of Korea.
authors.forename: Jong-Geun
authors.initials: JG
authors.lastname: Seo
authors.affiliation: Department of Neurology, School of Medicine, Kyungpook National University, Republic of Korea sppark@mail.knu.ac.kr.
authors.forename: Sung-Pa
authors.initials: SP
authors.lastname: Park
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002227:Carbazoles / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000150:complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000523:psychology; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D014363:Tryptamines / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D002227:Carbazoles; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C108128:frovatriptan
keywords: Migraine; depression; frovatriptan; response; risk factor